Top 5 Drug Type | Count |
---|---|
Small molecule drug | 16 |
Monoclonal antibody | 5 |
Recombinant coagulation factor | 1 |
Synthetic peptide | 1 |
Recombinant vector vaccine | 1 |
Target |
Mechanism CTLA4 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date21 Oct 2022 |
Target |
Mechanism TSLP inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date17 Dec 2021 |
Target |
Mechanism SARS-CoV-2 S protein inhibitors |
Active Org. |
Originator Org. |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date08 Dec 2021 |
Start Date19 Jan 2024 |
Sponsor / Collaborator ![]() [+1] |
Start Date07 Jul 2023 |
Sponsor / Collaborator |
Start Date15 Mar 2023 |
Sponsor / Collaborator ![]() [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Cilgavimab/Tixagevimab ( SARS-CoV-2 S protein ) | COVID-19 More | Approved |
Acalabrutinib ( BTK ) | Small Lymphocytic Lymphoma More | Approved |
Tamoxifen Citrate ( ER ) | Breast Cancer More | Approved |
Bicalutamide ( AR ) | Prostatic Cancer More | Approved |
Anifrolumab-FNIA ( IFNAR-1 ) | Systemic Lupus Erythematosus More | Approved |